The TLR2 agonists lipoteichoic acid and Pam3CSK4 induce greater pro-inflammatory responses than inactivated Mycobacterium butyricum

Cellular Immunology

Volumn 280, Issue 1, 2012, Pages 101-107

  Gambhir, Vandana ^a   Yildiz, Christopher ^a   Mulder, Rylend ^a   Siddiqui, Sarah ^a   Guzzo, Christina ^a   Szewczuk, Myron ^a   Gee, Katrina ^a   Basta, Sameh ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Cytokines; Mycobacterium; NF B; Nitric oxide; TLR

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOTEICHOIC ACID; MESSENGER RNA; NITRIC OXIDE; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; INFLAMMATION; MOUSE; MYCOBACTERIUM BUTYRICUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL LINE, TUMOR; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIPOPEPTIDES; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM; NF-KAPPA B; NITRIC OXIDE; TEICHOIC ACIDS; TOLL-LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

MYCOBACTERIUM; MYCOBACTERIUM BUTYRICUM;

EID: 84872175821     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.12.001     Document Type: Article

References (39)

1. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995.
2. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
3. Dziarski R., Gupta D. Staphylococcus aureus peptidoglycan is a toll-like receptor 2 activator: a reevaluation. Infect. Immun. 2005, 73:5212-5216.
4. Kimbrell M.R., Warshakoon H., Cromer J.R., Malladi S., Hood J.D., Balakrishna R., Scholdberg T.A., David S.A. Comparison of the immunostimulatory and proinflammatory activities of candidate gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells. Immunol. Lett. 2008, 118:132-141.
5. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., Takeda K., Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999, 11:443-451.
6. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
7. Casella C.R., Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid a as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 2008, 65:3231-3240.
8. Brunner R., Jensen-Jarolim E., Pali-Scholl I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol. Lett. 2010, 128:29-35.
9. Quesniaux V., Fremond C., Jacobs M., Parida S., Nicolle D., Yeremeev V., Bihl F., Erard F., Botha T., Drennan M., Soler M.N., Le Bert M., Schnyder B., Ryffel B. Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infect. 2004, 6:946-959.
10. Zuany-Amorim C., Hastewell J., Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat. Rev. Drug Discovery 2002, 1:797-807.
11. Brightbill H.D., Libraty D.H., Krutzik S.R., Yang R.B., Belisle J.T., Bleharski J.R., Maitland M., Norgard M.V., Plevy S.E., Smale S.T., Brennan P.J., Bloom B.R., Godowski P.J., Modlin R.L. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999, 285:732-736.
12. Lim S.K. Freund adjuvant induces TLR2 but not TLR4 expression in the liver of mice. Int. Immunopharmacol. 2003, 3:115-118.
13. Alatery A., Basta S. An efficient culture method for generating large quantities of mature mouse splenic macrophages. J. Immunol. Methods 2008, 338:47-57.
14. Alatery A., Siddiqui S., Chan M., Kus A., Petrof E.O., Basta S. Cross, but not direct, presentation of cell-associated virus antigens by spleen macrophages is influenced by their differentiation state. Immunol. Cell Biol. 2010, 88:3-12.
15. Siddiqui S., Alatery A., Kus A., Basta S. TLR engagement prior to virus infection influences MHC-I antigen presentation in an epitope-dependent manner as a result of nitric oxide release. J. Leukocyte Biol. 2011, 89:457-468.
16. He D., Wu L., Kim H.K., Li H., Elmets C.A., Xu H. CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J. Immunol. 2006, 177:6852-6858.
17. Yang Y.J., Chen S.H., Ge X.R. Role of interleukin-18 in the development of acute pulmonary injury induced by intestinal ischemia/reperfusion and its possible mechanism. J. Gastroenterol. Hepatol. 2007, 22:253-260.
18. Kyuhou S., Kato N., Gemba H. Emergence of endoplasmic reticulum stress and activated microglia in Purkinje cell degeneration mice. Neurosci. Lett. 2006, 396:91-96.
19. Guzzo C., Che Mat N.F., Gee K. Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes. J. Biol. Chem. 2010, 285:24404-24411.
20. Basta S., Stoessel R., Basler M., van den Broek M., Groettrup M. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J. Immunol. 2005, 175:796-805.
21. Alatery A., Tarrab E., Lamarre A., Basta S. The outcome of cross-priming during virus infection is not directly linked to the ability of the antigen to be cross-presented. Eur. J. Immunol. 2010, 40:2190-2199.
22. Siddiqui S., Basta S. CD8+ T cell immunodominance in lymphocytic choriomeningitis virus infection is modified in the presence of toll-like receptor agonists. J. Virol. 2011, 85:13224-13233.
23. Rees R.C., Potter C.W. Specific enhancement of transplantation immunity with heat-killed Mycobacterium butyricum and immunizing extracts from adenovirus 12-induced tumour cells. Br. J. Cancer 1972, 26:139-140.
24. Blander J.M. Phagocytosis and antigen presentation: a partnership initiated by toll-like receptors. Ann. Rheum. Dis. 2008, 67(Suppl. 3):iii44-49.
25. Kim J., Gambhir V., Alatery A., Basta S. Delivery of exogenous antigens to induce cytotoxic CD8+ T lymphocyte responses. J. Biomed. Biotechnol. 2010, 2010:218752.
26. Khanolkar A., Fuller M.J., Zajac A.J. T cell responses to viral infections: lessons from lymphocytic choriomeningitis virus. Immunol. Res. 2002, 26:309-321.
27. Pulendran B. Modulating vaccine responses with dendritic cells and toll-like receptors. Immunol. Rev. 2004, 199:227-250.
28. Aliprantis A.O., Yang R.B., Mark M.R., Suggett S., Devaux B., Radolf J.D., Klimpel G.R., Godowski P., Zychlinsky A. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999, 285:736-739.
29. Nair S., Pandey A.D., Mukhopadhyay S. The PPE18 protein of Mycobacterium tuberculosis inhibits NF-kappaB/rel-mediated proinflammatory cytokine production by upregulating and phosphorylating suppressor of cytokine signaling 3 protein. J. Immunol. 2011, 186:5413-5424.
30. Heldwein K.A., Liang M.D., Andresen T.K., Thomas K.E., Marty A.M., Cuesta N., Vogel S.N., Fenton M.J. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J. Leukocyte Biol. 2003, 74:277-286.
31. Saiga H., Shimada Y., Takeda K. Innate immune effectors in mycobacterial infection. Clin. Dev. Immunol. 2011, 2011:347594.
32. Basta S., Bennink J.R. A survival game of hide and seek: cytomegaloviruses and MHC class I antigen presentation pathways. Viral Immunol. 2003, 16:231-242.
33. Basta S., Alatery A. The cross-priming pathway: a portrait of an intricate immune system. Scand. J. Immunol. 2007, 65:311-319.
34. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., Davey G.M., Wilson N.S., Carbone F.R., Villadangos J.A. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 2004, 199:9-26.
35. Prajeeth C.K., Jirmo A.C., Krishnaswamy J.K., Ebensen T., Guzman C.A., Weiss S., Constabel H., Schmidt R.E., Behrens G.M. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. Eur. J. Immunol. 2010, 40:1272-1283.
36. Lemay C.G., Rintoul J.L., Kus A., Paterson J.M., Garcia V., Falls T.J., Ferreira L., Bridle B.W., Conrad D.P., Tang V.A., Diallo J.S., Arulanandam R., Le Boeuf F., Garson K., Vanderhyden B.C., Stojdl D.F., Lichty B.D., Atkins H.L., Parato K.A., Bell J.C., Auer R.C. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol. Ther. 2012, 20:1791-1799.
37. Dietrich N., Lienenklaus S., Weiss S., Gekara N.O. Murine toll-like receptor 2 activation induces type I interferon responses from endolysosomal compartments. PLoS One 2010, 5:e10250.
38. Weiss G., Rasmussen S., Zeuthen L.H., Nielsen B.N., Jarmer H., Jespersen L., Frokiaer H. Lactobacillus acidophilus induces virus immune defence genes in murine dendritic cells by a Toll-like receptor-2-dependent mechanism. Immunology 2010, 131:268-281.
39. Oh J.Z., Kurche J.S., Burchill M.A., Kedl R.M. TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 2011, 118:3028-3038.